A Multi-Centre, Randomised, Open-Label, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma
Latest Information Update: 14 Sep 2023
At a glance
- Drugs Fimaporfin/gemcitabine (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Cholangiocarcinoma
- Focus Registrational; Therapeutic Use
- Acronyms RELEASE
- Sponsors PCI Biotech
- 17 Feb 2023 According to a PCI Biotech media release, all major study closure activities for the RELEASE trial are completed and the estimated remaining cash effect for the closure process is less than NOK -1 million. Downsizing of the full clinical team, reported in August, was enacted during second half of 2022 with full cost reduction effect in Q1 2023.
- 28 Jul 2022 This trial has been completed in Germany (Date of the global end of the trial : 06-May-2022), according to European Clinical Trials Database record.
- 07 Jul 2022 This trial has been completed in Denmark (Date of the global end of the trial : 06-May-2022), according to European Clinical Trials Database record.